Simulating Tangle Spread Along Axons, Scientists Predict Tau PET Patterns
The modeling approach reinforces the idea that tau pathology propagates through the brain’s physical architecture, including neuronal networks.
ALL NEWS
452 RESULTS
Sort By:
- Most Recent
- Most Commented
In Colombian Alzheimer’s Kindred, Blood NfL Climbs 22 Years Before Symptoms
The plasma biomarker neurofilament light was able to distinguish individual mutation carriers from noncarriers three years prior to onset.
Could Tau PET Replace Amyloid Biomarkers as a Diagnostic for AD?
A large, cross-sectional study finds that RO-948 PET discriminates AD dementia from other disorders more accurately than do CSF biomarkers or MRI.
Does Alzheimer’s Start in the Heart of the Cholinergic System?
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.
Confused About the DIAN-TU Trial Data? Experts Discuss
The AAT-AD/PD conference hosted a virtual conversation about what the trial’s disappointing cognitive and tantalizing biomarker data might mean. Hidden between thank you’s and pledges to stay committed were substantive points of debate and context.
In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned
Data shown at AAT-AD/PD explain why the DIAN-TU trial missed its primary endpoint. But gantenerumab strongly reduced plaques, tau, phospho-tau, and slowed NfL. This result prompted an open-label extension, sustaining hope for efficacy.
217—The Best Phospho-Tau Marker for Alzheimer’s?
P-tau217 appears sooner than p-tau181 in the brain, and it distinguishes AD from controls and other dementias even more cleanly.
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better
At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.
A Phospho-Tau Plasma Assay for Alzheimer’s?
Two papers report that phosphorylated tau in the blood distinguishes people with AD from healthy controls and from people with frontotemporal and vascular dementias.
Different CSF Phospho-Taus Match Distinct Changes in Brain Pathology
Different forms of p-tau in cerebrospinal fluid reflect worsening plaque load, metabolism, and atrophy in the brain. They could help stage Alzheimer’s disease.
Tau2020: Meeting for Tauopathies Debuts Genetic Variants
By engaging scientists studying every tau-based disorder, a new conference aimed to foster collaborations and research directions.
How Much Amyloid Will Kick Off Tangles, and Decline?
At HAI 2020, scientists more precisely quantified the relationship between plaques, tangles, and cognitive decline.
Can PET Match Up Areas of Protein Deposit With Alzheimer’s Symptoms?
Amyloid and tau PET are helping scientists pinpoint the underlying cause of specific AD symptoms. Perhaps imaging of certain brain regions will help predict an individual’s progression.
Tau PET: The Field Expands Rapidly
At the HAI 2020 conference, the tracers PI-2620 and APN-1607 appeared to bind frontotemporal dementia tau. MK-6240 looked highly sensitive. And JNJ-067 and SNFT-1 are two new kids in town.
Multimodal Imaging of Neurodegenerative Diseases Links Pathology and Cellular Dysfunction
Synapse loss and mitochondrial stress, as seen by separate PET tracers, go hand-in-hand in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
Current Filters
- Biomarkers x